RxDoctor Payments Data

Tammy Uleberg, NP

Psychiatric/Mental Health · Minot, NDNPI 1710051628

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 85 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in ND with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,568in general payments, 2019–2025

Across 85 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$316
  • Alkermes, Inc.$214
  • Sunovion Pharmaceuticals Inc.$180
  • Otsuka America Pharmaceutical, Inc.$169
  • AbbVie$153
  • Axsome Therapeutics, Inc.$122
  • plus $415 from 10 others

What the payments were for

  • Food & beverage$1,568100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,568 in reported general payments places this provider in the 90th percentile of 92 psychiatric/mental health providers in North Dakota.

See all psychiatric/mental health providers in North Dakota

Medicare billing

Part B allowed, 2024
$6,276
Medicare patients
20
Services billed
63

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole19$41,500
Divalproex Sodium29$1,301
Quetiapine Fumarate23$1,272
Lurasidone Hcl29$1,036
Fluoxetine Hcl32$888
Aripiprazole27$868
Naltrexone Hcl13$841
Trazodone Hcl13$819
Bupropion XlBupropion Hcl32$788
Duloxetine Hcl42$774
Sertraline Hcl27$607
Buspirone Hcl39$409
Metformin Hcl ErMetformin Hcl18$349
Clonazepam46$254
Propranolol Hcl15$207

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$169$41,50019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 92 psychiatric/mental health providers in North Dakota.

Other psychiatric/mental health in Minot

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →